Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

February 14, 2023

https://www.globenewswire.com/news-release/2023/02/14/2607497/0/en/Sensei-Biotherapeutics-to-Present-New-Preclinical-Data-for-SNS-101-a-Conditionally-Active-VISTA-blocking-Antibody-at-the-Keystone-Symposia-on-Next-Generation-Antibody-Therapeutics.html

BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, will present new preclinical data on SNS-101, a conditionally active, pH-selective VISTA-blocking antibody, at Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Keystone Symposia, being held February 19-22, 2023 in Banff, Alberta, Canada. The presentation will be made by Sensei’s Chief Scientific Officer, Dr. Edward van der Horst.

Read more at globenewswire.com

Related news for (SNSE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.